Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in Patients Wild-Type KRAS Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy.

Next Previous
Trial Profile

Randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in Patients Wild-Type KRAS Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary) ; Cetuximab; Irinotecan
  • Indications Coecal cancer; Colorectal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Jun 2020 Results published in the European Journal of Cancer
    • 23 Oct 2018 Results combined analysis of ASPECCT and WJOG6510G demonstrating that Pmab significantly prolonged OS and PFS compared with Cmab ,presented at the 43rd European Society for Medical Oncology Congress.
    • 20 Jan 2018 Results of a pooled analysis in a subgroup of patients with prior bevacizumab from the ASPECCT and WJOG6510G trials (n=374) presented at the 2018 Gastrointestinal Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top